View web version

"A wave of patients will jump on [new gene therapy products] quickly, but it's going to be critical for companies to offer a full suite of products."

Hans Duerr
VP, Global Strategic Marketing, Hematology
Bayer HealthCare Pharmaceuticals


Will Gene Therapy
Go Mainstream?

The products are safe. The science is rock-solid. Patients are champing at the bit. But as much as the industry may be lining up behind gene therapies, marketing and operational questions abound. Larry Dobrow reports on the current state of the gene therapy union

CLICK HERE for full coverage of MM&M's Biotech Report from the August 2015 issue, including:

Exclusive interviews and expert commentary from:

  • Margaret Cianci, Executive Director, Alliance for Cancer Gene Therapy
  • Jörn Aldag, CEO, uniQure
  • Hans Duerr, VP, Global Strategic Marketing, Hematology, Bayer HealthCare Pharmaceuticals
  • Bob Finkel, CEO, FreshBlood
  • Amy Graham, General Manager, Ogilvy CommonHealth Specialty Marketing

Read the report. Share it instantly on Facebook, Twitter, Google+ and LinkedIn. Post your own comments. View or download a PDF of the beautifully designed original layout from the print edition of MM&M. It's all FREE and it's right here.

For details on how to advertise in The Splash from MM&M, please email Doreen Gates

To unsubscribe from the The Splash from MM&M click here.
To manage your entire MM&M profile login to your account.

You are subscribed as: %%EMAIL%%

To contact Haymarket Media for general questions or unsubscribe problems, please reply to this email.

All MM&M newsletters are sent from the domain "". When configuring e-mail or spam
filter rules, please use this domain name.

Medical Marketing & Media Magazine
114 W. 26th Street 4th Floor
New York N.Y. 10001
Phone: (646) 638-6000
Fax: (646) 638-6150

© 2015 Haymarket Media Inc.